The overlap between microbiome diversity and butyrate production is very strong. Below is a 7-day, food-first plan built around:
Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
Butyrate Prevents Chemotherapy Side Effects. Great. What is butyrate? Where is butyrate? How do I get butyrate into my system?
Spoiler alert. This post supports all my other blog posts about cancer patients enhancing their gut microbiome. Butyrate is one of the main ingredients of a diverse gut microbiome.
I’ve linked the video below to several blog posts because Dr. Specter presents easy, tasty methods for enhancing gut health as well as enhancing butyrate.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. In an effort to be a thorough cancer coach, I will research and post blogs that cite butyrate and it’s specific effect on a specific chemotherapy regimen. The research below focuses on Irinotecan (Camptosar), but I would like to broaden the list to other common chemo regimens.
Are you a cancer survivor about to undergo therapy with a specific regimen? Scroll down the page, post a question or comment, and I will reply to you ASAP.
Good luck,
It treats advanced, metastatic colorectal and pancreatic cancers. Irinotecan breaks cancer cell DNA. This prevents division and causes cell death. It is given intravenously. Common side effects are severe diarrhea, cholinergic syndrome (sweating, cramps), nausea, vomiting, hair loss, and low white blood cell counts.
Chemotherapy-induced gastrointestinal toxicity is a significant dose-limiting complication for cancer treatment. Disruption of the gastrointestinal (GI) epithelial barrier function by several chemotherapeutic agents results in development of mucositis and diarrhea.
Thus, maintaining barrier integrity may be of therapeutic benefit. Recent studies have shown the beneficial effects of the microbial metabolite butyrate, a short chain fatty acid (SCFA), on epithelial barrier integrity.
In this current study, we tested the effect of oral butyrate on irinotecan-induced gastrointestinal (GI) toxicity in mice. Irinotecan dose-dependently reduced body weight, increased fecal water content and increased gastrointestinal motility.
Acetylcholine induced contractions were markedly increased in colons of irinotecan treated mice as were nicotine-induced inward currents in isolated ileum myenteric neurons. Loperamide reduced GI motility of irinotecan treated mice, however tolerance developed with chronic use, consistent with clinical findings of loperamide refractory diarrhea in patients.
Oral butyrate improved epithelial permeability and prevented irinotecan-induced increase in β-glucuronidase activity in fecal samples. Irinotecan treatment produced a significant shift in the β diversity of the fecal microbiome that was mitigated by butyrate.
The microbial dysbiosis was associated with increases in the mucin degrading bacteria Akkermansia muciniphilia and the hydrogen sulfide producing Desulfovibrio sp10575755 that was reduced with butyrate treatment.
Butyrate Prevents Chemotherapy Side Effects Butyrate Prevents Chemotherapy Side Effects